Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents

Daniel M. Hays, Hlroyukl Shimada, R. Beverly Raney, Melvin Tefft, William Newton, William M. Crist, Lawrence Walter Lawrence, Abdel Ragab, Mohan Beltangady, Harold M. Maurer

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

From 1972 to 1984, 47 children and adolescents with primary tumors of the female genital tract were treated with eight different Intergroup Rhabdomyosarcoma Study (IRS I‐II) protocols. These included patients with vaginal (28), uterine (ten), or vulval (nine) rhabdomyosarcoma or undifferentiated sarcomas. The mean age of patients with primary vaginal tumors was younger than 2 years. All were of the embryonal histologic subtype. The majority of these patients were treated with initial chemotherapy (vincristine, dactinomycin, ±cyclophosphamide, ±Adriamycin [(ADR) doxorubicin]) followed by delayed hysterectomy and/or partial vaginectomy. Among 26 patients with localized vaginal tumors, there have been six relapses resulting in one tumor‐related death and one therapy‐related death. The five patients with nonfatal relapse have been disease‐free for from 2.5 to 6.5 years (mean, 4.4 years) since salvage therapy was commenced. The 19 patients without relapse have been continuously disease‐free for 1.5 to 12 years (mean, 5.34 years: median, 6 years). No patient that received ADR initially relapsed. Ten patients, with a mean age > 13 years, had primary uterine sarcomas and were treated by the same chemotherapy regimens. Six with polypoid localiized lesions, removed before chemotherapy, have remained disease‐free for 2.5 to 6.5 years. Four, with more extensive local lesions or disseminated disease, treated with chemotherapy only, died 2 to 11 months from diagnosis. Nine patients with rhabdomyosarcomas of the wlva (age, 1‐19 years) were managed by the same chemotherapy regimens ± radiotherapy. Resection was carried out initially or after chemotherapy. Eight of these have been disease‐free from 4 to 10 years (mean, 6.4 years); and one is alive with probable disease at 2.5 years.

Original languageEnglish (US)
Pages (from-to)1893-1903
Number of pages11
JournalCancer
Volume61
Issue number9
DOIs
StatePublished - May 1 1988

Fingerprint

Rhabdomyosarcoma
Drug Therapy
Doxorubicin
Therapeutics
Recurrence
Sarcoma
Salvage Therapy
Neoplasms
Dactinomycin
Vincristine
Hysterectomy
Cyclophosphamide
Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents. / Hays, Daniel M.; Shimada, Hlroyukl; Raney, R. Beverly; Tefft, Melvin; Newton, William; Crist, William M.; Walter Lawrence, Lawrence; Ragab, Abdel; Beltangady, Mohan; Maurer, Harold M.

In: Cancer, Vol. 61, No. 9, 01.05.1988, p. 1893-1903.

Research output: Contribution to journalArticle

Hays, DM, Shimada, H, Raney, RB, Tefft, M, Newton, W, Crist, WM, Walter Lawrence, L, Ragab, A, Beltangady, M & Maurer, HM 1988, 'Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents', Cancer, vol. 61, no. 9, pp. 1893-1903. https://doi.org/10.1002/1097-0142(19880501)61:9<1893::AID-CNCR2820610929>3.0.CO;2-9
Hays, Daniel M. ; Shimada, Hlroyukl ; Raney, R. Beverly ; Tefft, Melvin ; Newton, William ; Crist, William M. ; Walter Lawrence, Lawrence ; Ragab, Abdel ; Beltangady, Mohan ; Maurer, Harold M. / Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents. In: Cancer. 1988 ; Vol. 61, No. 9. pp. 1893-1903.
@article{41b3b481d75541eea937c548c8a203ff,
title = "Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents",
abstract = "From 1972 to 1984, 47 children and adolescents with primary tumors of the female genital tract were treated with eight different Intergroup Rhabdomyosarcoma Study (IRS I‐II) protocols. These included patients with vaginal (28), uterine (ten), or vulval (nine) rhabdomyosarcoma or undifferentiated sarcomas. The mean age of patients with primary vaginal tumors was younger than 2 years. All were of the embryonal histologic subtype. The majority of these patients were treated with initial chemotherapy (vincristine, dactinomycin, ±cyclophosphamide, ±Adriamycin [(ADR) doxorubicin]) followed by delayed hysterectomy and/or partial vaginectomy. Among 26 patients with localized vaginal tumors, there have been six relapses resulting in one tumor‐related death and one therapy‐related death. The five patients with nonfatal relapse have been disease‐free for from 2.5 to 6.5 years (mean, 4.4 years) since salvage therapy was commenced. The 19 patients without relapse have been continuously disease‐free for 1.5 to 12 years (mean, 5.34 years: median, 6 years). No patient that received ADR initially relapsed. Ten patients, with a mean age > 13 years, had primary uterine sarcomas and were treated by the same chemotherapy regimens. Six with polypoid localiized lesions, removed before chemotherapy, have remained disease‐free for 2.5 to 6.5 years. Four, with more extensive local lesions or disseminated disease, treated with chemotherapy only, died 2 to 11 months from diagnosis. Nine patients with rhabdomyosarcomas of the wlva (age, 1‐19 years) were managed by the same chemotherapy regimens ± radiotherapy. Resection was carried out initially or after chemotherapy. Eight of these have been disease‐free from 4 to 10 years (mean, 6.4 years); and one is alive with probable disease at 2.5 years.",
author = "Hays, {Daniel M.} and Hlroyukl Shimada and Raney, {R. Beverly} and Melvin Tefft and William Newton and Crist, {William M.} and {Walter Lawrence}, Lawrence and Abdel Ragab and Mohan Beltangady and Maurer, {Harold M.}",
year = "1988",
month = "5",
day = "1",
doi = "10.1002/1097-0142(19880501)61:9<1893::AID-CNCR2820610929>3.0.CO;2-9",
language = "English (US)",
volume = "61",
pages = "1893--1903",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents

AU - Hays, Daniel M.

AU - Shimada, Hlroyukl

AU - Raney, R. Beverly

AU - Tefft, Melvin

AU - Newton, William

AU - Crist, William M.

AU - Walter Lawrence, Lawrence

AU - Ragab, Abdel

AU - Beltangady, Mohan

AU - Maurer, Harold M.

PY - 1988/5/1

Y1 - 1988/5/1

N2 - From 1972 to 1984, 47 children and adolescents with primary tumors of the female genital tract were treated with eight different Intergroup Rhabdomyosarcoma Study (IRS I‐II) protocols. These included patients with vaginal (28), uterine (ten), or vulval (nine) rhabdomyosarcoma or undifferentiated sarcomas. The mean age of patients with primary vaginal tumors was younger than 2 years. All were of the embryonal histologic subtype. The majority of these patients were treated with initial chemotherapy (vincristine, dactinomycin, ±cyclophosphamide, ±Adriamycin [(ADR) doxorubicin]) followed by delayed hysterectomy and/or partial vaginectomy. Among 26 patients with localized vaginal tumors, there have been six relapses resulting in one tumor‐related death and one therapy‐related death. The five patients with nonfatal relapse have been disease‐free for from 2.5 to 6.5 years (mean, 4.4 years) since salvage therapy was commenced. The 19 patients without relapse have been continuously disease‐free for 1.5 to 12 years (mean, 5.34 years: median, 6 years). No patient that received ADR initially relapsed. Ten patients, with a mean age > 13 years, had primary uterine sarcomas and were treated by the same chemotherapy regimens. Six with polypoid localiized lesions, removed before chemotherapy, have remained disease‐free for 2.5 to 6.5 years. Four, with more extensive local lesions or disseminated disease, treated with chemotherapy only, died 2 to 11 months from diagnosis. Nine patients with rhabdomyosarcomas of the wlva (age, 1‐19 years) were managed by the same chemotherapy regimens ± radiotherapy. Resection was carried out initially or after chemotherapy. Eight of these have been disease‐free from 4 to 10 years (mean, 6.4 years); and one is alive with probable disease at 2.5 years.

AB - From 1972 to 1984, 47 children and adolescents with primary tumors of the female genital tract were treated with eight different Intergroup Rhabdomyosarcoma Study (IRS I‐II) protocols. These included patients with vaginal (28), uterine (ten), or vulval (nine) rhabdomyosarcoma or undifferentiated sarcomas. The mean age of patients with primary vaginal tumors was younger than 2 years. All were of the embryonal histologic subtype. The majority of these patients were treated with initial chemotherapy (vincristine, dactinomycin, ±cyclophosphamide, ±Adriamycin [(ADR) doxorubicin]) followed by delayed hysterectomy and/or partial vaginectomy. Among 26 patients with localized vaginal tumors, there have been six relapses resulting in one tumor‐related death and one therapy‐related death. The five patients with nonfatal relapse have been disease‐free for from 2.5 to 6.5 years (mean, 4.4 years) since salvage therapy was commenced. The 19 patients without relapse have been continuously disease‐free for 1.5 to 12 years (mean, 5.34 years: median, 6 years). No patient that received ADR initially relapsed. Ten patients, with a mean age > 13 years, had primary uterine sarcomas and were treated by the same chemotherapy regimens. Six with polypoid localiized lesions, removed before chemotherapy, have remained disease‐free for 2.5 to 6.5 years. Four, with more extensive local lesions or disseminated disease, treated with chemotherapy only, died 2 to 11 months from diagnosis. Nine patients with rhabdomyosarcomas of the wlva (age, 1‐19 years) were managed by the same chemotherapy regimens ± radiotherapy. Resection was carried out initially or after chemotherapy. Eight of these have been disease‐free from 4 to 10 years (mean, 6.4 years); and one is alive with probable disease at 2.5 years.

UR - http://www.scopus.com/inward/record.url?scp=0023928856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023928856&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19880501)61:9<1893::AID-CNCR2820610929>3.0.CO;2-9

DO - 10.1002/1097-0142(19880501)61:9<1893::AID-CNCR2820610929>3.0.CO;2-9

M3 - Article

C2 - 3281745

AN - SCOPUS:0023928856

VL - 61

SP - 1893

EP - 1903

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -